Home / Health / Schizophrenia Trial Sparks Hope for New Treatment
Schizophrenia Trial Sparks Hope for New Treatment
26 Mar
Summary
- Phase III trial is assessing LB-102 for schizophrenia.
- Nearly 460 patients will participate in the US-based study.
- Top-line results are anticipated in the second half of 2027.
LB Pharmaceuticals has commenced the pivotal Phase III NOVA-2 trial to evaluate LB-102, an investigational therapy for schizophrenia. This randomized, multi-center, placebo-controlled study will involve nearly 460 patients across 25 US sites, assessing the drug's safety and efficacy over six weeks.
The primary goal is to measure the variation in the Positive and Negative Syndrome Scale (PANSS) total score. Secondary endpoints will examine other symptom domains, cognitive function, and personal/social performance. An open-label extension study is also planned to further assess long-term safety and effects on negative symptoms and cognition.
LB Pharmaceuticals anticipates top-line results from the NOVA-2 trial in the second half of 2027. Positive outcomes could lead to a pre-new drug application meeting with the US FDA. LB-102 is an oral small molecule designed as a selective antagonist for D2, D3, and 5-HT7 receptors.
